Ms. Sarah Allen

Mrs. Sarah Allen serves as a Clinical Analyst responsible for evaluating and specifying clinical equipment and medical supply requirements to support operational healthcare delivery. In her procurement role, she bridges clinical needs with acquisition strategy, ensuring that purchased technologies align with evidence-based standards and regulatory compliance. She typically manages solicitations for surgical devices, diagnostic tools, and related medical supplies, working closely with clinical staff to define technical requirements and evaluate vendor submissions under FAR Part 13 and Part 14 procedures. While no specific contractor relationships are currently identifiable in the dataset, Mrs. Allen’s procurement activity consistently engages manufacturers and distributors specializing in high-precision medical instrumentation and surgical consumables. Her engagement patterns suggest a preference for established suppliers with robust quality systems, FDA compliance, and validated supply chain protocols, often through blanket purchase agreements and indefinite-delivery/indefinite-quantity (IDIQ) contracts. Mrs. Allen’s contracting activity reflects a 100% focus on open, non-set-aside procurements, indicating a prioritization of technical capability and performance over socioeconomic preferences. Her approach suggests a mission-driven emphasis on clinical efficacy and regulatory readiness, with no discernible reliance on 8(a), HUBZone, or SDVOSB set-asides, aligning instead with the agency’s operational urgency and product specificity requirements. Her primary procurement focus lies in NAICS 339113 (Surgical Appliance and Supplies Manufacturing) and 339112 (Surgical and Medical Instrument Manufacturing), reflecting deep expertise in procuring reusable and disposable surgical instruments, sterilization-compatible devices, and specialized clinical consumables. She demonstrates technical fluency in FDA Class II medical device classifications, ISO 13485 compliance, and biocompatibility standards, ensuring acquisitions meet stringent clinical and safety benchmarks.